The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Spinoff / Spinout | Alive

About SK Plasma

SK Plasma is a Korean healthcare company.

SK Plasma Headquarter Location

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SK Plasma News

10:15 EDT Worldwide Plasma Derived Medicine Industry to 2028 - Featuring Grifols, SK Plasma and Fusion Healthcare Among Others

Apr 20, 2022

News provided by Share this article Share this article Plasma-derived medicinal products are pharmaceuticals or medicines produced from human plasma which is the liquid portion of the blood and consists of approximately 90% water. It contains over 120 different proteins that take on functions vital to life, such as fighting infections or clotting of blood to stop bleeding after an injury. Albumin, immunoglobulin, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma. PDMPs (plasma-derived medicinal products) are used in medical treatment and prophylaxis. Plasma products play an important role in managing autoimmune disorders, bleeding emergencies, and a number of chronic conditions such as hemophilia, congenital and acquired immunodeficiencies, and other inherited protein disorders. Increasing product approvals by regulatory bodies for plasma-derived medicines are expected to drive the global plasma derived medicine market over the forecast period. For instance, in July 2021, Octapharma AG, a company that develops and produces high-quality human proteins from human plasma and human cell lines, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its Octagam 10%, an immune globulin intravenous (human) liquid preparation derived from large pools of human plasma, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease. Moreover, increasing marketing approvals by the regulatory bodies for plasma-derived medicines is expected to drive the global plasma derived medicine market over the forecast period. For instance, in January 2022, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, announced that the National Medical Products Administration (NMPA) for China granted BPL a license to market ALBUMINEX 25% product in China. Key features of the study: This report provides an in-depth analysis of the global plasma derived medicine market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players It profiles key players in the global plasma derived medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Grifols, S.A., SK Plasma, Fusion Healthcare, Takeda Pharmaceutical Company Limited, LFB, Octapharma AG, CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc., Kamada Pharmaceuticals, and Biotest AG Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics The global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market Key Topics Covered: 2. Market Purview Market Dynamics Overall Impact

  • What is SK Plasma's latest funding round?

    SK Plasma's latest funding round is Spinoff / Spinout.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.